Tocilizumab en artritis reumatoide

Reumatología Clínica - Tập 6 - Trang 29-32 - 2011
Javier Rueda Gotor1, Ricardo Blanco Alonso1
1Servicio de Reumatología, Hospital Universitario Marqués de Valdecilla, Santander, España

Tài liệu tham khảo

Pablos Álvarez, 2009, La interleucina 6 en la fisiopatología de la artrirtis reumatoide, Reumatol Clin., 5, 10.1016/S1699-258X(09)70203-7 Maini, 2006, Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate, Arthritis Rheum., 54, 2817, 10.1002/art.22033 Nishimoto, 2009, Mod Rheumatol., 19, 12, 10.1007/s10165-008-0125-1 Nishimoto, 2007, Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI). Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab, Ann Rheum Dis., 66, 1162, 10.1136/ard.2006.068064 Smolen, 2008, Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial, Lancet., 371, 989, 10.1016/S0140-6736(08)60453-5 Kremer, 2008, Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: The LITHE study, Arthritis Rheum., 589, L11 Genovese, 2008, Arthritis Rheum., 58, 2968, 10.1002/art.23940 Emery, 2008, IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial, Ann Rheum Dis., 67, 516, 10.1136/ard.2008.092932 Jones, 2010, Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study, Ann Rheum Dis., 69, 88, 10.1136/ard.2008.105197 Rubbert-Roth, 2009, Interim Results of the TAMARA Study Effectiveness and Safety of the Interleukin-6 (IL-6) Receptor Antagonist Tocilizumab After 4 and 24 Weeks in Patients with Active Rheumatoid Arthritis (RA) [abstract], Arthritis Rheum., 60, 412 Bykerk, 2010, Tocilizumab in patients with rheumatoid arthritis and an inadequate response to dmards and/or tnf inhibitor therapy: ACT-SURE preliminary results, Ann Rheum Dis., 69, 379 Smolen, 2010, Efficacy of tocilizumab in patients with ra and inadequate response to DMARDs or TNF inhibitors: up to 3.5-year data from ongoing extension studies, Ann Rheum Dis., 69, 386 Jones, 2010, Efficacy of Tocilizumab in patients with rheumatoid arthritis who had never been exposed to or had never failed methotrexate: analysis of up to 3 years of treatment in a long-term extension study, Ann Rheum Dis., 69, 386 Smolen, 2008, Safety of tocilizumab in patients with rheumatoid arthritis: Pooled analysis of five phase 3 clinical trials, Arthritis Rheum., 589 Suppl, 1669 Van Vollenhoven, 2010, Safety of tocilizumab in patients with rheumatoid arthritis: analysis of median of 2.6 years of treatment in long-term extension studies, Ann Rheum Dis., 69, 544